

elementary and secondary students.
Respondents include various

components of State Human Service
agencies.

Respondents: The 52 respondents
include the 50 States, the District of
Columbia, and Puerto Rico.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Annual Statistical Report on Children in Foster Homes and Children Receiving Payments in Excess of the Poverty Level From a State Program Funded Under Part A of Title IV of the Social Security Act	52	1	264.35	13,746.20

*Estimated Total Annual Burden
Hours:* 13,746.20.

Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 330
C Street SW., Washington, DC 20201.
Attention Reports Clearance Officer. All
requests should be identified by the title
of the information collection. Email
address: infocollection@acf.hhs.gov.

OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the **Federal Register**.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email: OIRA_SUBMISSION@OMB.EOP.GOV, Attn:
Desk Officer for the Administration for
Children and Families.

Robert Sargis,
Reports Clearance Officer.

[FR Doc. 2017-26353 Filed 12-6-17; 8:45 am]

BILLING CODE 4184-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-6476]

Pediatric Rare Diseases—A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a draft
guidance for industry entitled “Pediatric

Rare Diseases—A Collaborative
Approach for Drug Development Using
Gaucher Disease as a Model.” This draft
guidance focuses on drug development
for pediatric patients with Gaucher
disease. In particular, it proposes for
consideration a novel approach to
improve the efficiency of drug
development in pediatric rare diseases
using Gaucher disease as an example.
The emergence of concomitant trials for
multiple investigational drug products
for the treatment of rare diseases can
pose significant challenges to effective
drug development, because there are
limited numbers of patients for any
given rare condition worldwide. This
approach discusses the feasibility of the
development of multiple drug products
in a time-efficient manner while
minimizing the number of patients
necessary to be treated with placebo.

DATES: Submit either electronic or
written comments on the draft guidance
by February 5, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.

ADDRESSES: You may submit comments
on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the
following way:

- *Federal eRulemaking Portal:*
<https://www.regulations.gov>. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to <https://www.regulations.gov> will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your

comments, that information will be
posted on <https://www.regulations.gov>.

- If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see “Written/Paper
Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as
follows:

- *Mail/Hand delivery/Courier (for
written/paper submissions):* Dockets
Management Staff (HFA-305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in “Instructions.”

Instructions: All submissions received
must include the Docket No. FDA-
2017-N-6476 for “Pediatric Rare
Diseases—A Collaborative Approach for
Drug Development Using Gaucher
Disease as a Model; Draft Guidance for
Industry; Availability”. Received
comments will be placed in the docket
and, except for those submitted as
“Confidential Submissions,” publicly
viewable at <https://www.regulations.gov>
or at the Dockets Management Staff
office between 9 a.m. and 4 p.m.,
Monday through Friday.

- *Confidential Submissions*—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
“THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.” The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information

redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Hong Vu, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5345, Silver Spring, MD 20993-0002, 301-796-7401.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance for industry entitled "Pediatric Rare Diseases—A Collaborative Approach for Drug Development Using Gaucher Disease as a Model." The emergence of concomitant trials for multiple investigational drug products for the treatment of rare disease can pose significant challenges to effective drug development, given the limited number of patients worldwide with these diagnoses. This guidance discusses,

among other things, a multi-arm, multi-company clinical trial as a novel approach to enhance the efficiency of drug development in pediatric rare diseases using pediatric Gaucher disease as an example. The proposal applies only to systemic (*i.e.*, non-neurological) manifestations of Gaucher disease (*i.e.*, patients with Type I and Type III phenotypes).

The purpose of this guidance is to facilitate drug development in pediatric rare diseases, with a focus on Gaucher disease. In this guidance, Gaucher disease is provided as a disease model. However, the principles underlying this proposal may be extended to other areas of drug development in rare diseases. The guidance was originally a document developed as a strategic collaboration between FDA and the European Medicines Agency to enhance the efficiency of drug development in Gaucher disease, which was released in 2014 for public comment. The draft guidance is an updated version of the document and has no fundamental changes to the original intent and content.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on "Pediatric Rare Diseases—A Collaborative Approach for Drug Development Using Gaucher Disease as a Model." It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. This guidance is not subject to Executive Order 12866.

II. The Paperwork Reduction Act of 1995

This draft guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 21 CFR parts 312 and 314 have been approved under OMB control numbers 0910-0014 and 0910-0001, respectively. The collections of information in 21 CFR 201.57 for the content and format of prescription drug labeling was approved under OMB control number 0910-0572.

III. Electronic Access

Persons with access to the internet may obtain the draft guidance at either <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/>

[Guidances/default.htm](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm) or <https://www.regulations.gov>.

Dated: December 1, 2017.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2017-26357 Filed 12-6-17; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1161]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food Safety Survey

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by January 8, 2018.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to oir_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0345. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRASStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Food Safety Survey

OMB Control Number 0910-0345—Extension

Under section 1003(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(b)(2)), we are authorized